Multivariate Analysis of Molecular Indicators for Postoperative Liver Metastasis in Colorectal Cancer Cases

  • Qian, Li-Yuan (Department of General Surgery, Xiangya Third Hospital, Central South University) ;
  • Li, Ping (Department of Burn and Plastics Surgery, Xiangya Third Hospital, Central South University) ;
  • Li, Xiao-Rong (Department of General Surgery, Xiangya Third Hospital, Central South University) ;
  • Chen, Dao-Jin (Department of General Surgery, Xiangya Third Hospital, Central South University) ;
  • Zhu, Shai-Hong (Department of General Surgery, Xiangya Third Hospital, Central South University)
  • Published : 2012.08.31


Aims: To explore the relationship between various molecular makers and liver metastasis of colorectal cancer (CRC). Method: Using immunohistochemistry, protein expression of CEA, nm23, c-met, MMP2, COX-2, VEGF, EGFR, and CD44 was assessed in 80 CRC cases. The Chi-square test and logistic regression were performed to analyze the relationship between these indicators and CRC liver metastasis. Results: There were significant differences in expression of CEA, MMP2, CD44, VEGF and EGFR between the liver metastasis and non metastasis groups (P < 0.05); no significant differences were noted for nm23, c-met, and COX-2 expression. Logistic regression analysis showed that only CEA, VEGF, and EGFR entered into the regression equation, and had significant correlations with CRC liver metastasis (${\alpha}$ inclusion= 0.10, ${\alpha}$ elimination = 0.15, R2 = 0.718). Conclusions: Combination detection of CEA, VEGF, and EGFR may be an effective means to predict CRC liver metastasis. Nm23, c-met, MMP2, COX-2, and CD44, in contrast, are not suitable as prognostic markers.


  1. Aruffo A, Stamenkovic I, Melnick M, et al (1990). CD44 is the principal cell surface receptor for hyaluronate. Cell, 61, 1303-13.
  2. Bakalakos EA (1999). Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg, 177, 2-6.
  3. Bentrem DJ, DeMatteo RP, Blumgart LH (2005). Surgical therapy for metastatic disease to the liver. Annu Rev Med, 56, 139-56.
  4. Bird NC, Mangnall D and Majeed AW (2006). Biology of colorectal liver metastases: a review. J Surg Oncol, 94, 68-80.
  5. Cao D, Hou M, Guan Y, et al (2009). Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC cancer, 9, 432.
  6. Chung-Faye GA, Kerr DJ, Young LS, et al (2000). Gene therapy strategies for colon cancer. Mol Med Tod, 6, 82-7.
  7. Cox D, Pontes C, Guino E, et al (2004). Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer, 91, 339-43.
  8. Di Renzo MF, Olivero M, Giacomini A, et al (1995). Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res, 1, 147.
  9. Dong W, Li H, Zhang Y, et al (2011). Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai), 43, 840-8.
  10. Dursun A, Akyurek N, Gunel N, et al (2002). Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology, 34, 427-32.
  11. Ellis LM (2003). Biology of colorectal liver metastases. Surg Oncol Clin N Am, 12, 135-50.
  12. Gill SE, Parks WC (2011). Matrix metalloproteinases and their inhibitors in turnover and degradation of extracellular matrix. Extracellular Matrix Degradation, 1-22.
  13. Huang X, Sheng Y, Guan M (2012). Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis. Surg Oncol, 21, 103-7.
  14. Kaulfu$\beta$ S, Burfeind P, Gaedcke J, et al (2009). Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther, 8, 821-33.
  15. Kuramochi H, Hayashi K, Nakajima G, et al (2010). Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. Cancer Chemother Pharmacol, 65, 825-31.
  16. Liu LX, Zhang WH, Jiang HC (2003). Current treatment for liver metastases from colorectal cancer. World J Gastrointest Surg, 9, 193-200.
  17. Nanashima A, Yamaguchi H, Sawai T, et al (1999). Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol, 14, 1004-9.
  18. Okada N, Ishida H, Murata N, et al (2001). Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer. Biochem Biophys Res Commun, 288, 212-6.
  19. Pessaux P, Lermite E, Brehant O, et al (2006). Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol, 93, 1-7.
  20. Porte RJ (2009). Epidemiology, Etiology, and Natural History of Colorectal Liver Metastases. Malignant Liver Tumors, 64-8.
  21. Seibert K, Zhang Y, Leahy K, et al (1997). Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol, 400, 167-70.
  22. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst, 101, 1308-24.
  23. Thomson D, Krupey J, Freedman S, et al (1969). The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A, 64, 161-7.
  24. Tokunaga T, Oshika Y, Abe Y, et al (1998). Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer, 77, 998-1002.
  25. Wang J, Lu C, Chu K, et al (2007). Prognostic significance of preand postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res, 39, 245-50.
  26. Wang S, Liu H, Ren L, et al (2008). Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia, 10, 399-407.
  27. Yamaguchi A, Urano T, Fushida S, et al (1993). Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. Br J Cancer, 68, 1020-4.
  28. Yao M, Lam E, Kelly C, et al (2004). Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer, 90, 712-9.
  29. Zafirellis K, Agrogiannis G, Zachaki A, et al (2008). Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res, 147, 99-107.
  30. Zeng ZS, Cohen AM, Guillem JG (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP- 9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749-55.
  31. Zeng ZS, Weiser MR, Kuntz E, et al (2008). c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett, 265, 258-69.
  32. Zheng S, Chen K, Liu X, et al (2003). Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum, 46, 51-8.

Cited by

  1. Down-regulated MYH11 Expression Correlates with Poor Prognosis in Stage II and III Colorectal Cancer vol.15, pp.17, 2014,
  2. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis vol.36, pp.2, 2015,